WO2005003777A3 - Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences - Google Patents

Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences Download PDF

Info

Publication number
WO2005003777A3
WO2005003777A3 PCT/US2004/020700 US2004020700W WO2005003777A3 WO 2005003777 A3 WO2005003777 A3 WO 2005003777A3 US 2004020700 W US2004020700 W US 2004020700W WO 2005003777 A3 WO2005003777 A3 WO 2005003777A3
Authority
WO
WIPO (PCT)
Prior art keywords
enzyme
nucleic acid
enhanced
acid sequences
metal deposition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/020700
Other languages
French (fr)
Other versions
WO2005003777A2 (en
Inventor
Christopher Bieniarz
Casey A Kernag
Jerome W Kosmeder
Paula M Rodgers
Jennifer Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ventana Medical Systems Inc
Original Assignee
Ventana Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Medical Systems Inc filed Critical Ventana Medical Systems Inc
Priority to CA2530287A priority Critical patent/CA2530287C/en
Priority to JP2006517725A priority patent/JP4648902B2/en
Priority to AU2004254386A priority patent/AU2004254386B2/en
Priority to DK04756257T priority patent/DK1636586T3/en
Priority to EP04756257A priority patent/EP1636586B1/en
Priority to DE602004022165T priority patent/DE602004022165D1/en
Priority to AT04756257T priority patent/ATE437369T1/en
Publication of WO2005003777A2 publication Critical patent/WO2005003777A2/en
Publication of WO2005003777A3 publication Critical patent/WO2005003777A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Chemically Coating (AREA)
  • Manufacture Of Alloys Or Alloy Compounds (AREA)

Abstract

The invention is directed to novel compositions of matter and methods of detecting in situ an immunohistochemical epitope or nucleic acid sequence of interest in a biological sample comprising binding an enzyme-labeled conjugate molecule to the epitope or sequence of interest in the presence of a redox-inactive reductive species and a soluble metal ion, thereby facilitating the reduction of the metal ion to a metal atom at or about the point where the enzyme is anchored. Novel phosphate derivatives of reducing agents are described that when exposed to a phosphatase are activated to their reducing form, thereby reducing metal ions to insoluble metal.
PCT/US2004/020700 2003-06-24 2004-06-24 Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences Ceased WO2005003777A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2530287A CA2530287C (en) 2003-06-24 2004-06-24 Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences
JP2006517725A JP4648902B2 (en) 2003-06-24 2004-06-24 Enzyme-catalyzed metal attachment for improved in situ detection of immunohistochemical epitopes and nucleic acid sequences
AU2004254386A AU2004254386B2 (en) 2003-06-24 2004-06-24 Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences
DK04756257T DK1636586T3 (en) 2003-06-24 2004-06-24 Enzyme-catalyzed metal deposition for enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences
EP04756257A EP1636586B1 (en) 2003-06-24 2004-06-24 Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences
DE602004022165T DE602004022165D1 (en) 2003-06-24 2004-06-24 ENZYME CATALYSED METAL DEPOSITION FOR REINFORCED AND NUCLEIC ACID SEQUENCES
AT04756257T ATE437369T1 (en) 2003-06-24 2004-06-24 ENZYME-CATALYzed METAL DEPOSITION FOR ENHANCED IN-SITU DETECTION OF IMMUNOHISTOLOGICAL EPITOPES AND NUCLEIC ACID SEQUENCES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48259603P 2003-06-24 2003-06-24
US60/482,596 2003-06-24

Publications (2)

Publication Number Publication Date
WO2005003777A2 WO2005003777A2 (en) 2005-01-13
WO2005003777A3 true WO2005003777A3 (en) 2005-06-09

Family

ID=33563868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/020700 Ceased WO2005003777A2 (en) 2003-06-24 2004-06-24 Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences

Country Status (10)

Country Link
US (1) US7632652B2 (en)
EP (1) EP1636586B1 (en)
JP (1) JP4648902B2 (en)
AT (1) ATE437369T1 (en)
AU (1) AU2004254386B2 (en)
CA (2) CA2773566C (en)
DE (1) DE602004022165D1 (en)
DK (1) DK1636586T3 (en)
ES (1) ES2330441T3 (en)
WO (1) WO2005003777A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017954B2 (en) 2007-05-23 2015-04-28 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1565747B1 (en) * 2001-03-29 2013-11-27 Cellect Technologies Corp. Method and system for separating and sorting particles
US7691598B2 (en) * 2001-03-30 2010-04-06 Nanoprobes, Inc. Method for detecting a target molecule by metal deposition
US7888060B2 (en) * 2001-03-30 2011-02-15 Nanoprobes, Inc. Method for detecting a target using enzyme directed deposition of elemental metal
US7642064B2 (en) 2003-06-24 2010-01-05 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest
JP5628476B2 (en) * 2005-04-28 2014-11-19 ベンタナ・メデイカル・システムズ・インコーポレーテツド Antibody conjugate
ES2548518T3 (en) 2005-11-23 2015-10-19 Ventana Medical Systems, Inc. Molecular conjugate
US7695929B2 (en) 2006-11-01 2010-04-13 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
JP4920553B2 (en) * 2006-11-08 2012-04-18 富士フイルム株式会社 Immunochromatographic kit
FR2924601A1 (en) * 2007-12-07 2009-06-12 Oreal Composition, useful for depigmenting and/or bleaching of human skin, body hair or hair and to prepare dermatological composition, comprises hydroquinone diphosphate compound in a medium
DK2995925T3 (en) 2008-06-05 2022-02-21 Ventana Med Syst Inc Composition for histochemical processing
EP2334827B1 (en) 2008-08-22 2015-03-11 Ventana Medical Systems, Inc. Method for chromogenic detection of two or more target molecules in a single sample
KR101027036B1 (en) * 2009-05-28 2011-04-11 주식회사 인포피아 Signal amplification method in lateral flow analysis by reduction of gold ions and lateral flow analysis device using the same
SG182303A1 (en) 2009-12-31 2012-08-30 Ventana Med Syst Inc Methods for producing uniquely specific nucleic acid probes
ES2606012T3 (en) 2010-02-26 2017-03-17 Ventana Medical Systems, Inc. In situ hybridization with PolyTag probes
US9040310B2 (en) 2010-04-27 2015-05-26 Ventana Medical Systems, Inc. Antibody-nanoparticle conjugates and methods for making and using such conjugates
WO2012003478A2 (en) * 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Detecting targets using mass tags and mass spectrometry
WO2012055060A1 (en) 2010-10-28 2012-05-03 Eth Zurich Method for electrical detection of biomolecules by metal dissolution and assay kit therefore
DK2659000T3 (en) 2010-12-30 2016-08-29 Ventana Med Syst Inc ENHANCED DEPOSIT OF Chromogens USING pyrimidine
US8703439B1 (en) 2011-01-31 2014-04-22 Linda Lester Point of care iodine sensor
CN103534359B (en) 2011-03-14 2016-07-06 文塔纳医疗系统公司 Analyze method and the system thereof of chromosome translocation
AU2012251027B2 (en) 2011-05-04 2015-03-26 Htg Molecular Diagnostics, Inc. Quantitative nuclease protection Assay (qNPA) and sequencing (qNPS) improvements
WO2013167387A1 (en) 2012-05-10 2013-11-14 Ventana Medical Systems, Inc. Uniquely specific probes for pten, pik3ca, met, top2a, and mdm2
WO2014009535A2 (en) 2012-07-12 2014-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
WO2014048942A1 (en) 2012-09-25 2014-04-03 Ventana Medical Systems, Inc. Probes for pten, pik3ca, met, and top2a, and method for using the probes
US9938523B2 (en) * 2013-03-15 2018-04-10 Arizona Board Of Regents On Behalf Of Arizona State University Nucleic acid-tagged compositions and methods for multiplexed protein-protein interaction profiling
WO2015036405A1 (en) 2013-09-10 2015-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating basal cell carcinoma
EP3066218B1 (en) 2013-11-05 2018-12-26 HTG Molecular Diagnostics, Inc. Methods for detecting nucleic acids
EP3617322A1 (en) 2014-02-24 2020-03-04 Ventana Medical Systems, Inc. Automated rna detection using labeled 2 -o-methyl rna oligonucleotide probes and signal amplification systems
EP3152577B1 (en) 2014-06-06 2018-07-18 Ventana Medical Systems, Inc. Significance of intratumoral her2 heterogeneity in breast cancer and uses therefor
AU2015326827B2 (en) 2014-10-02 2019-11-07 Ventana Medical Systems, Inc. Polymers and conjugates comprising the same
EP3009147A1 (en) 2014-10-16 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant glioblastoma
WO2016124558A1 (en) 2015-02-03 2016-08-11 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
AU2016232223A1 (en) 2015-03-16 2017-08-31 University Of Washington Materials and methods for detecting androgen receptor splice variants and uses thereof
EP3283522A1 (en) 2015-04-17 2018-02-21 Spring Bioscience Corporation Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
WO2016189065A1 (en) 2015-05-26 2016-12-01 Ventana Medical Systems, Inc. Method and system for assessing stain quality for in-situ hybridization and immunohistochemistry
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
WO2017055319A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of b cells in a tissue sample
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055321A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055325A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of nk cells in a tissue sample
WO2017055320A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
WO2017067944A1 (en) 2015-10-19 2017-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from triple negative breast cancer
JP6876062B2 (en) 2016-01-26 2021-05-26 ヴェンタナ メディカル システムズ， インク． Predictive diagnostic workflow for tumors with automated disection, next-generation sequencing, and automated slide staining equipment
AU2017229370B2 (en) 2016-03-08 2021-03-11 Ventana Medical Systems, Inc. Multiplexed immunohistochemistry using recombinant antibodies with epitope tags
WO2017182834A1 (en) 2016-04-19 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating resistant glioblastoma
EP3463452A1 (en) 2016-05-24 2019-04-10 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
WO2018011107A1 (en) 2016-07-11 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of er-alpha 46 in methods and kits for assessing the status of breast cancer
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2018046736A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
WO2018055080A1 (en) 2016-09-22 2018-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
WO2018055014A1 (en) 2016-09-23 2018-03-29 Ventana Medical Systems, Inc. Methods and systems for scoring extracellular matrix biomarkers in tumor samples
WO2018091419A1 (en) 2016-11-15 2018-05-24 Ventana Medical Systems, Inc. Compositions and methods for prognosing and treating colorectal cancer
CN110121364A (en) 2016-12-19 2019-08-13 文塔纳医疗系统公司 Peptide nucleic acid conjugate
WO2018118786A1 (en) 2016-12-19 2018-06-28 Ventana Medical Systems, Inc. Methods and systems for quantitative immunohistochemistry
WO2018122249A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
WO2018122245A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
WO2018146239A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarker for outcome in aml patients
WO2018162404A1 (en) 2017-03-06 2018-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarker for outcome in aml patients
WO2018172540A1 (en) 2017-03-24 2018-09-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to predict the progression of alzheimer's disease
WO2018189215A1 (en) 2017-04-12 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the survival time of a patient suffering from hepatocellular carcinoma
US12566174B2 (en) 2017-05-11 2026-03-03 The Research Foundation For The State University Of New York Method and kit for determining the presence of monosodium urate crystals in joint synovial fluid
CN107189988B (en) * 2017-07-17 2019-08-30 江南大学 A hybridoma cell line CS12 secreting anti-eugenol monoclonal antibody and its application
EP3659110A1 (en) 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
WO2019038219A1 (en) 2017-08-21 2019-02-28 INSERM (Institut National de la Santé et de la Recherche Médicale) NEW PROGNOSTIC METHOD OF PANCREATIC CANCER
WO2019043138A1 (en) 2017-09-01 2019-03-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the outcome of a cancer
US11579147B2 (en) 2017-09-25 2023-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of VNN1 as a biomarker and a therapeutic target in sarcomas
WO2019120635A1 (en) 2017-12-18 2019-06-27 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates
ES2965647T3 (en) 2018-01-31 2024-04-16 Ventana Med Syst Inc Procedures and systems for the evaluation of immune cell infiltrate in stage III colorectal cancer
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
WO2019224153A1 (en) 2018-05-21 2019-11-28 Genentech, Inc. Her2 heterogeneity as a biomarker in cancer
EP3824288A1 (en) 2018-07-17 2021-05-26 Ventana Medical Systems, Inc. Materials and methods for detecting fusion proteins
CN112673258B (en) 2018-09-13 2025-07-25 文塔纳医疗系统公司 Histochemical and cytochemical methods for detection of NTRK fusion proteins
CN112789684B (en) 2018-10-01 2025-05-09 文塔纳医疗系统公司 Methods and systems for predicting response to PD-1 axis-directed therapy
WO2020089428A1 (en) 2018-11-02 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method of pancreatic cancer
WO2020089432A1 (en) 2018-11-02 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method of pancreatic cancer
JP7548903B2 (en) 2018-11-20 2024-09-10 ヴェンタナ メディカル システムズ， インク． Methods and systems for preparing and analyzing cell samples for morphological characteristics and biomarker expression - Patents.com
WO2020141199A1 (en) 2019-01-03 2020-07-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
JP2022522265A (en) 2019-01-16 2022-04-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Erythroferrone mutants and their use
JP7411667B2 (en) 2019-02-05 2024-01-11 ヴェンタナ メディカル システムズ， インク． Methods and systems for assessment of immune cell infiltration in stage IV colorectal cancer
US20220098674A1 (en) 2019-02-13 2022-03-31 Inserm (Institut National De La Santé Et Dr La Recherch Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
WO2020182932A1 (en) 2019-03-13 2020-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) New gene signatures for predicting survival time in patients suffering from renal cell carcinoma
WO2020193740A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
JP2022530390A (en) 2019-04-24 2022-06-29 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods for Predicting Antipsychotic Responses
WO2020229521A1 (en) 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for inhibiting or reducing bacterial biofilms on a surface
WO2021001539A1 (en) 2019-07-04 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy to detect and treat eosinophilic fasciitis
US20220340975A1 (en) 2019-09-05 2022-10-27 INSERM (Institute National de la Santé et de la Recherche Médicale) Method of treatment and pronostic of acute myeloid leukemia
US20240301497A1 (en) 2019-10-17 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing nasal intestinal type adenocarcinomas
WO2021173674A1 (en) 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
WO2021170777A1 (en) 2020-02-28 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
EP4121768A1 (en) 2020-03-20 2023-01-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the survival time of a patient suffering from a cancer
CN115552248A (en) 2020-05-07 2022-12-30 文塔纳医疗系统公司 Tissue chemistry systems and methods for evaluating EGFR and EGFR ligand expression in tumor samples
JP2023528978A (en) 2020-06-10 2023-07-06 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods for treating and preventing cancers such as malignant glioblastoma
US20230218608A1 (en) 2020-06-18 2023-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2022018163A1 (en) 2020-07-22 2022-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting survival time in patients suffering from cancer
WO2022063787A1 (en) 2020-09-22 2022-03-31 Roche Diagnostics Gmbh Antibodies specific for alpha-1,6-core-fucosylated psa and fucosylated fragments thereof
WO2022064049A1 (en) 2020-09-28 2022-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing brucella infection
WO2022084327A1 (en) 2020-10-20 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the response to tnf inhibitors
WO2022096633A1 (en) 2020-11-06 2022-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and treating polycystic ovary syndrome (pcos)
WO2022135753A1 (en) 2020-12-21 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for prognosis the humoral response of a subject prior to vaccination
WO2022136252A1 (en) 2020-12-21 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for prognosis the humoral response of a subject prior to vaccination
WO2022152698A1 (en) 2021-01-12 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of npdk-d to evaluate cancer prognosis
US20240044901A1 (en) 2021-02-09 2024-02-08 Institut National de la Santé et de la Recherche Médicale New method to pronostic lung cancer
EP4308934A1 (en) 2021-03-17 2024-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing pancreatic cancer
WO2022207566A1 (en) 2021-03-29 2022-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to evaluate pancreatic cancer prognosis
EP4326903A1 (en) 2021-04-23 2024-02-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating cell senescence accumulation related disease
EP4367269A1 (en) 2021-07-05 2024-05-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
WO2023089159A1 (en) 2021-11-22 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy targeting stroma/tumor cell crosstalk to treat a cancer
EP4472740A1 (en) 2022-01-31 2024-12-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2023152133A1 (en) 2022-02-08 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing colorectal cancer
WO2024061930A1 (en) 2022-09-22 2024-03-28 Institut National de la Santé et de la Recherche Médicale New method to treat and diagnose peripheral t-cell lymphoma (ptcl)
WO2024115935A1 (en) 2022-11-29 2024-06-06 Inserm Methods for the treatment of b-cell lymphoma using cd39 inhibitors
WO2024236131A1 (en) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Stratificate and method to treat a patient suffering from a cancer
WO2024245951A1 (en) 2023-05-26 2024-12-05 Institut National de la Santé et de la Recherche Médicale Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
WO2025027127A1 (en) 2023-08-02 2025-02-06 Institut National de la Santé et de la Recherche Médicale New prognostic method of kidney failure
WO2025045894A1 (en) 2023-08-28 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods and kits for diagnosing cause of nephrotic syndrome and guiding therapy
WO2025068340A1 (en) 2023-09-27 2025-04-03 Institut National de la Santé et de la Recherche Médicale Method to predict aml outcome
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025078632A1 (en) 2023-10-12 2025-04-17 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from cancer
WO2025109147A1 (en) 2023-11-24 2025-05-30 Institut National de la Santé et de la Recherche Médicale Method to predict the risk of a cardiovascular event in a patient with type 2 diabetes
WO2025114473A1 (en) 2023-11-29 2025-06-05 Institut National de la Santé et de la Recherche Médicale Method for assessing diseases associated with a loss of p53 function in subjects in need thereof
WO2026013153A1 (en) 2024-07-10 2026-01-15 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from myc-high tumors
WO2026093526A1 (en) 2024-10-31 2026-05-07 Institut National de la Santé et de la Recherche Médicale Methods of predicting cancer in patients having premalignant lesions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073483A (en) * 1988-03-25 1991-12-17 Bioprobe Systems Method of staining nucleic acids detected by non-radioactive labelling and kit of reactants for carrying out the method
US5116734A (en) * 1989-09-01 1992-05-26 Digene Diagnostics, Inc. Highly sensitive method for detecting peroxidase
US20020142411A1 (en) * 2001-03-30 2002-10-03 Hainfeld James F. Enzymatic deposition and alteration of metals
WO2003035900A1 (en) * 2001-10-24 2003-05-01 Michael Burton Enzyme activity indicators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491098A (en) * 1987-03-09 1996-02-13 Janssen Pharmaceutica N.V. Method for depositing metal particles on a marker
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5252743A (en) * 1989-11-13 1993-10-12 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
US5595707A (en) * 1990-03-02 1997-01-21 Ventana Medical Systems, Inc. Automated biological reaction apparatus
ES2155822T3 (en) 1990-12-06 2001-06-01 Affymetrix Inc COMPOUNDS AND ITS USE IN A BINARY SYNTHESIS STRATEGY.
US5696887A (en) * 1991-08-05 1997-12-09 Biotek Solutions, Incorporated Automated tissue assay using standardized chemicals and packages
US5355439A (en) * 1991-08-05 1994-10-11 Bio Tek Instruments Method and apparatus for automated tissue assay
US5412087A (en) * 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5677195A (en) * 1991-11-22 1997-10-14 Affymax Technologies N.V. Combinatorial strategies for polymer synthesis
US5631734A (en) * 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
WO1995030774A1 (en) * 1994-05-05 1995-11-16 Beckman Instruments, Inc. Oligonucleotide repeat arrays
US5571639A (en) * 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5599695A (en) * 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US6093574A (en) * 1997-08-11 2000-07-25 Ventana Medical Systems Method and apparatus for rinsing a microscope slide
US6083726A (en) * 1998-02-03 2000-07-04 Lucent Technologies, Inc. Methods for polynucleotide synthesis and articles for polynucleotide hybridization
US6451683B1 (en) * 2000-08-28 2002-09-17 Micron Technology, Inc. Damascene structure and method of making

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073483A (en) * 1988-03-25 1991-12-17 Bioprobe Systems Method of staining nucleic acids detected by non-radioactive labelling and kit of reactants for carrying out the method
US5116734A (en) * 1989-09-01 1992-05-26 Digene Diagnostics, Inc. Highly sensitive method for detecting peroxidase
US20020142411A1 (en) * 2001-03-30 2002-10-03 Hainfeld James F. Enzymatic deposition and alteration of metals
WO2003035900A1 (en) * 2001-10-24 2003-05-01 Michael Burton Enzyme activity indicators

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1983, MEUR S K ET AL: "A NEW TECHNIQUE FOR LOCALIZATION OF CELLULASE IN-SITU USING SILVER NITRATE", XP002305553, Database accession no. PREV198477046809 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1984, PARTANEN S: "A DIRECT COLORING METAL PRECIPITATION METHOD FOR THE DEMONSTRATION OF ARYL SULFATASE A AND ARYL SULFATASE B", XP002305554, Database accession no. PREV198478052564 *
HISTOCHEMICAL JOURNAL, vol. 16, no. 5, 1984, pages 501 - 506, ISSN: 0018-2214 *
PATTON W F: "Detection technologies in proteome analysis", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 771, no. 1-2, 5 May 2002 (2002-05-05), pages 3 - 31, XP004350527, ISSN: 1570-0232 *
STAIN TECHNOLOGY, vol. 58, no. 2, 1983, pages 97 - 100, ISSN: 0038-9153 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017954B2 (en) 2007-05-23 2015-04-28 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US9103822B2 (en) 2007-05-23 2015-08-11 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US9575067B2 (en) 2007-05-23 2017-02-21 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization

Also Published As

Publication number Publication date
EP1636586B1 (en) 2009-07-22
CA2530287A1 (en) 2005-01-13
ES2330441T3 (en) 2009-12-10
ATE437369T1 (en) 2009-08-15
DK1636586T3 (en) 2009-11-23
CA2773566A1 (en) 2005-01-13
CA2773566C (en) 2015-09-15
DE602004022165D1 (en) 2009-09-03
CA2530287C (en) 2012-06-19
AU2004254386B2 (en) 2009-09-24
AU2004254386A1 (en) 2005-01-13
US7632652B2 (en) 2009-12-15
WO2005003777A2 (en) 2005-01-13
JP4648902B2 (en) 2011-03-09
US20040265922A1 (en) 2004-12-30
JP2007528986A (en) 2007-10-18
EP1636586A2 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
DK1636586T3 (en) Enzyme-catalyzed metal deposition for enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences
WO2001036470A3 (en) Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides
AU4073297A (en) Methods and compositions for the detection of cervical cancer
WO2004092708A3 (en) Methods for the electrochemical detection of target compounds
EP1379693A4 (en) Bio-barcodes based on oligonucleotide-modified particles
Waentig et al. Comparison of different chelates for lanthanide labeling of antibodies and application in a Western blot immunoassay combined with detection by laser ablation (LA-) ICP-MS
ATE555202T1 (en) METHOD FOR DELIVERING RNA INTERFERENCE AND USES THEREOF
WO2000052210A3 (en) Methods for targeting rna molecules
WO2005003394A3 (en) Bio-barcode based detection of target analytes
WO2003045310A3 (en) Digital assay
WO2012050963A2 (en) Agents providing controls and standards for immuno-precipitation assays
WO2005123954A3 (en) Methods for target molecule detection using siderophores and related compositions
WO2006034278A3 (en) Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
WO2004060915A3 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
WO2005062947A3 (en) Methods and compositions for identifying rna-binding proteins
Namdarghanbari et al. Toxic metal proteomics: Reaction of the mammalian zinc proteome with Cd2+
WO2001021826A3 (en) Detecting the presence of the pyruvate kinase isoenzyme in feces
WO2004074325A3 (en) Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
WO2002078636A3 (en) Detection and treatment of colorectal cancer
ATE272718T1 (en) METHOD FOR DETERMINING DISACCHARIDASES
WO2002075314A3 (en) Detection and treatment of prostate cancer
WO2008036474A3 (en) A method to detect tumor markers and diagnosis of undifferenciated tumors
WO2004099784A3 (en) Method for determining a tissue degradation process by detection of fibromodulin neoepitopes
EP1677739A4 (en) Methods of identifying agents that inhibit the growth of cancer cells
AU2002358143A1 (en) Method for determining molecule-molecule interaction in proteomics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004254386

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004254386

Country of ref document: AU

Date of ref document: 20040624

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2004756257

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004254386

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006517725

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2530287

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2004756257

Country of ref document: EP